Eplontersen for Hereditary Transthyretin Amyloidosis With Po

This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am

Related Keywords

Argentina , Rio De Janeiro , Estado Do Rio , Brazil , Funder , Midtjylland , Denmark , France , Spain , Boston , Massachusetts , United States , Germany , Turkey , Taiwan , Cyprus , Copenhagen , Køavn , Portugal , Canada , Sweden , New Zealand , Italy , Cidade Universitaria , Australia , American , Alnylam Pharmacauticals , Marques Jr , Clementino Fraga Filho , Waddington Cruz , Ionis Astrazeneca , Rodolpho Paulo Rocco , Intellia Regeneron , Research To Practice , Pfizer , American Academy Of Neurology Annual Meeting , Ionis Pharmaceuticals , Ionis Pharmaceuticals Inc , University Of Rio De Janeiro , Aptitude Health , Bristol Myers Squibb , Novo Nordisk , Group Information , Astrazeneca , Drug Administration , Alnylam Pharmaceuticals , Peripheral Nerve Society Annual Meeting , International Council For Harmonisation , Johnson , Mayo Clinic Peripheral Nerve Research Laboratory , American Society Of Hematology , Item Short Form , Neuropathy Impairment Score , Norfolk Quality , Life Questionnaire , Diabetic Neuropathy , Trials Register , International Council , Study Design , Meso Scale Discovery , Mayo Clinic , Peripheral Nerve Research Laboratory , Item Short Form Survey , Medical Dictionary , Regulatory Activities , Size Calculation , Post Hoc Analyses , Hospital Universit , Federal University , Drs Coelho , Interest Disclosures , American Society , Akcea Therapeutics , Intellia Therapeutics , Hoffmann La Roche , Physicians Education Resource , American Academy , Neurology Annual Meeting ,